Mesna inactivates platinum agents in vitro

Anticancer Research

Volumn 18, Issue 6 A, 1998, Pages 4077-4081

  Wolff, Johannes E A ^a,b   Egeler, R Maarten ^a,b   Anderson, Ron ^a   Ujack, Eva ^b   Iceton, Shannon ^a   Coppes, Max J ^a,b  

^a ALBERTA CHILDREN'S HOSPITAL   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Chemotherapy; Malignant glioma; Mesna; Platinum agents

Indexed keywords

CARBOPLATIN; CISPLATIN; MESNA; PLATINUM COMPLEX;

ARTICLE; CELL COUNT; CELL GROWTH; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; DRUG INACTIVATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARBOPLATIN; CELL SURVIVAL; CISPLATIN; GLIOMA; HUMANS; KINETICS; MESNA; PROTECTIVE AGENTS; TUMOR CELLS, CULTURED;

EID: 0032434930     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Howe-Grant ME, Lipard SJ: Aqueous platinum (II) chemistry: binding to biological molecules. In: Metal Ions In Biological Systems, Metal Complexes as Anticancer Agents. New York, Marcel Dekker, 99 (11), 1980.
2. Leeuwenkamp OR, Neijt JP, van der Vijgh WJ. Pinedo HM: Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di)mesna and thiosulphate. Eur J Cancer 27: 1243-1247, 1991.
3. Ormstadt K, Orrenius S, Lastbom T, et al: Pharmacokinetics and metabolism of sodium 2- mercaptoethanesulfonate in the rat. Cancer Res 43: 333-338, 1983.
4. Allan SG, Smyth JF, Hay FG, Leonard RC, Wolf CR: Protective effect of sodium-2- mercaptoethanesulfonate on the gastrointestinal toxicity and lethality of cis- diamminedichloroplatinum. Cancer Res 46: 3569-3573, 1986.
5. Dorr RT, Lagel K. Interaction between cisplatin and mesna in mice. J Cancer Res Clin Oncol 115: 605-605, 1989.
6. Mosman T: Rapid colorimetric assay for cellular growth and cytotoxicity assays. J Immunol Methods 65: 55, 1983.
7. Hansen M, Nielsen SE, Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203-210, 1989.
8. Brock N, Pohl J, Stekar J, Scheef W: Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention-III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Eur J Cancer Clin Oncol 18: 1377-1387, 1982.
9. Dorr RT: Chemoprotectants for cancer chemotherapy. Semin Oncol. 18(1 Suppl 2): 48-58, 1991.
10. Dorr RT: Chemoprotectants for cancer chemotherapy. Semin Oncol. 18(1 Suppl 2): 48-58, 1991.
11. Wolff IEA, Bilzer T, Stark M, Gobel U, Wechsler U: Effects of cisplatinum and carboplatinum on human glioma cells in vitro. J Cell Pharmacol 1: 99-101, 1994.
12. Wolff JEA, Denecke J, Jurgens H: Dexamethasone induces partial resistance to cisplatinum in C6 glioma cells. Anticancer Res 16: 805-810, 1996.
13. Glass J, Silverman CL, Axelrod R, Corn BW, Andrews DW: Fractionated stereotactic radiotherapy with cisplatin radiosensitization in the treatment of recurrent, progressive or persistent malignant astrocytoma. Am J Clin Oncol 20: 226-229, 1997.
14. Dropcho EJ, Rosenfeld SS, Morawetz RB, Vitek J, Brothers M, Gorum T, Bell S, Gillespie GY, Glantz M, Mahaley Ms Jr et al: preradiation intracarotic cisplatin treatment of newly diagnosed anaplastic gliomas. The CNS Cancer Consortium. J Clin Oncol 10: 452-458 1992.
15. Sovell VM, O'Conner T: Interaction of aquated cis NHPtII with nucleic acid constituents: 1. Ribonucleosides. Am J Chem Soc 99: 120-126, 1977.
16. Wolff JEA, Bilzer T, Stark M, Gobel U, Wechsler U: Effects of cisplatinum and carboplatinum on human glioma cells in vitro. J Cell Pharmacol 1: 99-101, 1994.
17. Wolff JEA, Bilzer T, Stark M, Gobel U, Wechsler U: Effects of cisplatinum and carboplatinum on human glioma cells in vitro. J Cell Pharmacol 1: 99-101, 1994.
18. Stein ME, Ruff P, Weaving A, Fried J, Bezwoda WR: A phase II study of cisplatin/ifosfamide in recurrent/metastatic undifferentiated nasopharyngeal carcinoma among young blacks in Southern Africa. Am J of Clin Oncol 19: 386-388, 1996.
19. Elias AD, Ayash LJ, Eder JP, et al: A phase I study of high dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol 9: 320-327, 1991.
20. Postmus PE, Scagliotti G, Groen HJ, et al: Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial. Eur J Cancer 32A: 1498-1503, 1996.
21. Pratt CB, Luo X, Fang L, Marina N, Avery L, Furman WL: Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: a single hospital experience. Med Pediatr Oncol 27: 145-148, 1996.